VYNE THERAPEUTICS INC. – Trademark Portfolio
Entity Type: 03
VYNE THERAPEUTICS INC. holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 12 trademarks are registered and 1 is pending. Notable registered marks include VYNE, ZILXI, AMZEEQ, FOAMIX, and VYNE THERAPEUTICS. The owner is based in BRIDGEWATER, NJ.
520 U.S. HIGHWAY 22
SUITE 204
BRIDGEWATER, NJ 08807
Showing of trademarks Trademarks
Trademark Classifications
VYNE THERAPEUTICS INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does VYNE THERAPEUTICS INC. have?
VYNE THERAPEUTICS INC. has 17 U.S. trademarks filed with the USPTO. Of these, 12 registered, 1 pending, 3 abandoned, 1 cancelled.
What trademark classes does VYNE THERAPEUTICS INC. file in?
VYNE THERAPEUTICS INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are VYNE THERAPEUTICS INC.'s most well-known trademarks?
VYNE THERAPEUTICS INC.'s registered trademark portfolio includes well-known marks such as VYNE, ZILXI, AMZEEQ, FOAMIX, and VYNE THERAPEUTICS. These are among 12 currently registered trademarks in the portfolio.
What is VYNE THERAPEUTICS INC.'s trademark registration success rate?
VYNE THERAPEUTICS INC. has a 75% trademark registration rate, with 12 out of 16 resolved applications resulting in successful registration. Currently, 1 application is pending review.